145 related articles for article (PubMed ID: 31853972)
21. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.
Mandorfer M; Reiberger T; Payer BA; Ferlitsch A; Breitenecker F; Aichelburg MC; Obermayer-Pietsch B; Rieger A; Trauner M; Peck-Radosavljevic M;
AIDS; 2013 Jan; 27(2):227-32. PubMed ID: 23238552
[TBL] [Abstract][Full Text] [Related]
22. Dynamics of serum metabolites in patients with chronic hepatitis C receiving pegylated interferon plus ribavirin: a metabolomics analysis.
Saito T; Sugimoto M; Igarashi K; Saito K; Shao L; Katsumi T; Tomita K; Sato C; Okumoto K; Nishise Y; Watanabe H; Tomita M; Ueno Y; Soga T
Metabolism; 2013 Nov; 62(11):1577-86. PubMed ID: 23953890
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.
Hu CC; Lin CL; Kuo YL; Chien CH; Chen SW; Yen CL; Lin CY; Chien RN
Aliment Pharmacol Ther; 2013 Jan; 37(1):81-90. PubMed ID: 23121150
[TBL] [Abstract][Full Text] [Related]
24. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
[TBL] [Abstract][Full Text] [Related]
25. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
26. A 12-week rescue therapy by PrOD-based regimen for advanced fibrotic genotype-1 CHC patients who failed to pegylated interferon plus ribavirin.
Wu SH; Chu CJ; Lin CC; Su CW; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
J Chin Med Assoc; 2019 Mar; 82(3):186-190. PubMed ID: 30908411
[TBL] [Abstract][Full Text] [Related]
27. A Taiwanese Nationwide Cohort Study Shows Interferon-Based Therapy for Chronic Hepatitis C Reduces the Risk of Chronic Kidney Disease.
Chen YC; Hwang SJ; Li CY; Wu CP; Lin LC
Medicine (Baltimore); 2015 Aug; 94(32):e1334. PubMed ID: 26266379
[TBL] [Abstract][Full Text] [Related]
28. Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis.
Dolatimehr F; Karimi-Sari H; Rezaee-Zavareh MS; Alavian SM; Behnava B; Gholami-Fesharaki M; Sharafi H
Daru; 2017 Apr; 25(1):11. PubMed ID: 28427463
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C].
Feng B; Shang J; Wu SH; Chen H; Han Y; Li YQ; Zhang DZ; Zhao LF; Wei SF; Mao Q; Yin CB; Han T; Wang MR; Chen SJ; Li J; Xie Q; Zhen Z; Gao ZL; Zhang YX; Gong GZ; Yang DL; Pan C; Sheng JF; Tang H; Ning Q; Shi GF; Niu JQ; Luo GH; Sun YT; You H; Wang GQ; Zhang LL; Peng J; Zhang Q; Liu JJ; Chen CW; Chen XY; Zhao W; Wang RH; Sun L; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):187-194. PubMed ID: 28482405
[No Abstract] [Full Text] [Related]
30. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.
Harrison SA; Brunt EM; Qazi RA; Oliver DA; Neuschwander-Tetri BA; Di Bisceglie AM; Bacon BR
Clin Gastroenterol Hepatol; 2005 Jun; 3(6):604-9. PubMed ID: 15952103
[TBL] [Abstract][Full Text] [Related]
31. [Dynamic changes in PD-1, TLR3, and TLR4 surface expression on peripheral blood mononuclear cells in chronic hepatitis C patients undergoing peg-IFNalpha-2a plus ribavirin combination therapy].
Zhang M; Jiang YF; Xiao XQ; Liu SF; Peng ML; Liu D; Gong GZ
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):196-201. PubMed ID: 23967741
[TBL] [Abstract][Full Text] [Related]
32. All Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C.
Shahid I; Ibrahim MM
Curr Mol Med; 2018; 18(7):409-435. PubMed ID: 30608042
[TBL] [Abstract][Full Text] [Related]
33. [Clinical observation of Hashimoto thyroiditis in patients with chronic hepatitis C undergoing pegylated-interferon alpha-2a and ribavirin combination therapy].
Teng ZL; Gong WJ; Zhang SQ; Sun YX; Ma XH
Zhonghua Gan Zang Bing Za Zhi; 2013 Feb; 21(2):101-4. PubMed ID: 23663880
[TBL] [Abstract][Full Text] [Related]
34. Patients younger than forty years old with hepatitis C virus genotype-1 chronic infection had treatment responses similar to genotype-2 infection and not related to interleukin-28B polymorphism.
Lin CY; Sheen IS; Jeng WJ; Huang CW; Huang CH; Chen JY
Ann Hepatol; 2013; 12(1):62-9. PubMed ID: 23293195
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
[TBL] [Abstract][Full Text] [Related]
36. Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study.
Liu CH; Yu ML; Peng CY; Hsieh TY; Huang YH; Su WW; Cheng PN; Lin CL; Lo CC; Chen CY; Chen JJ; Ma Q; Brooks-Rooney C; Kao JH
J Formos Med Assoc; 2019 Jun; 118(6):1014-1023. PubMed ID: 30448077
[TBL] [Abstract][Full Text] [Related]
37. Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
Dieterich D; Nelson M; Soriano V; Arastéh K; Guardiola JM; Rockstroh JK; Bhagani S; Laguno M; Tural C; Ingiliz P; Jain MK; Stern JO; Manero M; Vinisko R; Kort J;
AIDS; 2015 Mar; 29(5):571-81. PubMed ID: 25710287
[TBL] [Abstract][Full Text] [Related]
38. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
[TBL] [Abstract][Full Text] [Related]
39. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J;
Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
[TBL] [Abstract][Full Text] [Related]
40. Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir.
Vo KP; Vutien P; Akiyama MJ; Vu VD; Ha NB; Piotrowski JI; Wantuck J; Roytman MM; Tsai N; Cheung R; Li J; Nguyen MH
Dig Dis Sci; 2015 Apr; 60(4):1045-51. PubMed ID: 25821099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]